Ocugen (OCGN) EBIT (2014 - 2026)

Ocugen (OCGN) has 13 years of EBIT data on file, last reported at -$17.8 million in Q1 2026.

• Quarterly EBIT fell 23.02% year-over-year to -$17.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$66.3 million (down 16.15% YoY) and the FY2025 annual result came in at -$62.9 million, down 14.9% from the prior year.
• EBIT retreated to -$17.8 million in Q1 2026, from -$17.0 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$11.5 million in Q4 2023 to a low of -$25.1 million in Q3 2022.
• A 5-year average of -$17.1 million and a median of -$17.0 million in 2025 frame the typical range for EBIT.
• Annual changes were most pronounced in 2022 — EBIT slumped 169.66% — and 2023, when it surged 50.65%.
• Tracing OCGN's EBIT over 5 years: stood at -$23.4 million in 2022, then soared by 50.65% to -$11.5 million in 2023, then declined by 20.09% to -$13.8 million in 2024, then decreased by 22.8% to -$17.0 million in 2025, then slipped by 4.97% to -$17.8 million in 2026.
• The last three EBIT figures came in at -$17.8 million (Q1 2026), -$17.0 million (Q4 2025), and -$17.6 million (Q3 2025), per Business Quant data.